Literature DB >> 16971413

NT-proBNP reflects right ventricular structure and function in pulmonary hypertension.

C T Gan1, G P McCann, J T Marcus, S A van Wolferen, J W Twisk, A Boonstra, P E Postmus, A Vonk-Noordegraaf.   

Abstract

The aim of the current study was to investigate whether alterations in N-terminal pro brain natriuretic peptide (NT-proBNP) reflect changes in right ventricular structure and function in pulmonary hypertension patients during treatment. The study consisted of 30 pulmonary hypertension patients; 15 newly diagnosed and 15 on long-term treatment. NT-proBNP, right heart catheterisation and cardiac magnetic resonance imaging measurements were performed, at baseline and follow-up. There were no significant differences between newly diagnosed patients and those on treatment at baseline or follow-up with respect to NT-proBNP, haemodynamics and right ventricular parameters. Relative changes in NT-proBNP during treatment were correlated to the relative changes in right ventricular end-diastolic volume index (r = 0.59), right ventricular mass index (r = 0.62) and right ventricular ejection fraction (r = -0.81). N-terminal pro brain natriuretic peptide measurements reflect changes in magnetic resonance imaging-measured right ventricular structure and function in pulmonary hypertension patients. An increase in N-terminal pro brain natriuretic peptide over time reflects right ventricular dilatation concomitant to hypertrophy and deterioration of systolic function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16971413     DOI: 10.1183/09031936.00016006

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  21 in total

Review 1.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

2.  4,4'-Methylenedianiline Alters Serotonergic Transport in a Novel, Sex-Specific Model of Pulmonary Arterial Hypertension in Rats.

Authors:  Michelle Carroll-Turpin; Valeria Hebert; Tanya Chotibut; Heather Wensler; Dallas Krentzel; Kurt James Varner; Brendan R Burn; Yi-Fan Chen; Fleurette Abreo; Tammy Renee Dugas
Journal:  Toxicol Sci       Date:  2015-06-26       Impact factor: 4.849

Review 3.  Pulmonary hypertension survival effects and treatment options in cystic fibrosis.

Authors:  Adriano R Tonelli
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

4.  Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension.

Authors:  Mark R Toshner; Deepa Gopalan; Jay Suntharalingam; Carmen Treacy; Elaine Soon; Karen K Sheares; Nicholas W Morrell; Nicholas Screaton; Joanna Pepke-Zaba
Journal:  J Heart Lung Transplant       Date:  2010-03-15       Impact factor: 10.247

5.  Right Ventricular Tissue Doppler Myocardial Performance Index in Children with Pulmonary Hypertension: Relation to Invasive Hemodynamics.

Authors:  Richard M Friesen; Michal Schäfer; Dale A Burkett; Courtney J Cassidy; D Dunbar Ivy; Pei-Ni Jone
Journal:  Pediatr Cardiol       Date:  2017-10-04       Impact factor: 1.655

6.  N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pre-capillary pulmonary hypertension and renal insufficiency.

Authors:  Lars Harbaum; Jan K Hennigs; Hans J Baumann; Nicole Lüneburg; Elisabeth Griesch; Carsten Bokemeyer; Ekkehard Grünig; Hans Klose
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

7.  The predictive capabilities of a novel cardiovascular magnetic resonance derived marker of cardiopulmonary reserve on established prognostic surrogate markers in patients with pulmonary vascular disease: results of a longitudinal pilot study.

Authors:  Timothy J Baillie; Samuel Sidharta; Peter M Steele; Stephen G Worthley; Scott Willoughby; Karen Teo; Prashanthan Sanders; Stephen J Nicholls; Matthew I Worthley
Journal:  J Cardiovasc Magn Reson       Date:  2017-01-09       Impact factor: 5.364

Review 8.  Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.

Authors:  Pavel Jansa; Tomás Pulido
Journal:  Am J Cardiovasc Drugs       Date:  2018-02       Impact factor: 3.571

9.  SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Pavel Jansa; Tomás Pulido; Richard N Channick; Marion Delcroix; Hossein-Ardeschir Ghofrani; Franck-Olivier Le Brun; Sanjay Mehta; Loïc Perchenet; Lewis J Rubin; B K S Sastry; Gérald Simonneau; Olivier Sitbon; Rogério Souza; Adam Torbicki
Journal:  Eur Heart J       Date:  2017-04-14       Impact factor: 29.983

10.  Circulating biomarkers of interstitial lung disease in systemic sclerosis.

Authors:  Harpreet K Lota; Elisabetta A Renzoni
Journal:  Int J Rheumatol       Date:  2012-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.